Literature DB >> 8722044

Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state.

H Fujiwara1, T Hamaoka.   

Abstract

Tumor-bearing hosts develop antitumor immune responses. However, a number of immunosuppressive mechanisms come into operation with the progression of tumor growth. This article will review the observations regarding the modulation of antitumor immune responses in the tumor-bearing state, and consider the mechanisms underlying tumor-induced immune defects, especially in the light of the induction of an abnormal cytokine network. We will also describe the restoration of suppressed antitumor immune responses by administration of a particular cytokine, interleukin-12.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8722044     DOI: 10.1007/BF02935625

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  106 in total

1.  Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.

Authors:  D E Kern; J P Klarnet; M C Jensen; P D Greenberg
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

Review 2.  Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.

Authors:  K E Hellström; I Hellström
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

Review 3.  Tumor antigens.

Authors:  G Klein
Journal:  Annu Rev Microbiol       Date:  1966       Impact factor: 15.500

4.  Autologous peptides constitutively occupy the antigen binding site on Ia.

Authors:  S Buus; A Sette; S M Colon; H M Grey
Journal:  Science       Date:  1988-11-18       Impact factor: 47.728

Review 5.  The T cell receptor/CD3 complex: a dynamic protein ensemble.

Authors:  H Clevers; B Alarcon; T Wileman; C Terhorst
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

6.  IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice.

Authors:  D Aderka; J M Le; J Vilcek
Journal:  J Immunol       Date:  1989-12-01       Impact factor: 5.422

7.  Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor).

Authors:  M K Gately; B B Desai; A G Wolitzky; P M Quinn; C M Dwyer; F J Podlaski; P C Familletti; F Sinigaglia; R Chizonnite; U Gubler
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

8.  Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors.

Authors:  M A Collart; D Belin; J D Vassalli; S de Kossodo; P Vassalli
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

9.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.

Authors:  M Kobayashi; L Fitz; M Ryan; R M Hewick; S C Clark; S Chan; R Loudon; F Sherman; B Perussia; G Trinchieri
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

10.  Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA.

Authors:  B Bouchard; B B Fuller; S Vijayasaradhi; A N Houghton
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

View more
  3 in total

1.  The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma.

Authors:  Claire Verschraegen
Journal:  Cancer Manag Res       Date:  2012-01-18       Impact factor: 3.989

2.  Brucea javanica oil emulsion injection (BJOEI) as an adjunctive therapy for patients with advanced colorectal carcinoma: A protocol for a systematic review and meta-analysis.

Authors:  Chunhong Xu; Xinxin Guo; Changhui Zhou; Hualing Zhang
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

Review 3.  The Impact of Javanica Oil Emulsion Injection on Chemotherapy Efficacy and Cellular Immune Indicators in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis.

Authors:  Huilin Xu; Zhucheng Yin; Anbing He; Dedong Cao
Journal:  Evid Based Complement Alternat Med       Date:  2019-10-22       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.